Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) reported continued progress in intermediate-scale manufacturing and process development for key precursor components of ONC010, the company's lead nanoparticle-formulated oncology candidate. The work, conducted with Dalton Pharma Services as part of Onco's integrated chemistry, manufacturing and controls strategy, focuses on process optimization, analytical characterization and manufacturing reproducibility to support future GMP production, regulatory readiness and planned first-in-human clinical development activities in Australia.
This milestone is significant as Onco-Innovations moves closer to clinical trials for ONC010, which targets solid tumors. The company has secured an exclusive worldwide license to patented technology for this candidate. The manufacturing scale-up is critical to ensuring that ONC010 can be produced consistently and in sufficient quantities for clinical testing, a key requirement for regulatory approval. By partnering with Dalton Pharma Services, a contract development and manufacturing organization, Onco leverages expertise in pharmaceutical production to streamline the path to the clinic.
The announcement underscores the company's commitment to advancing its oncology pipeline. For Onco-Innovations, a Canadian-based company dedicated to cancer research and treatment, the progress in manufacturing is essential for transitioning from preclinical development to human trials. The company's mission focuses on pursuing the prevention and treatment of cancer through pioneering research and innovative solutions. The successful scale-up of ONC010 could pave the way for new treatment options for patients with solid tumors, addressing a significant unmet medical need.
Investors and stakeholders will be watching closely as Onco-Innovations continues to develop its lead candidate. The company's ability to achieve manufacturing reproducibility and regulatory readiness will be crucial for its long-term success. For more information about the company and its technology, visit https://oncoinnovations.com/. The full press release detailing the manufacturing progress is available at https://ibn.fm/Unt8n.
